Furthermore, in order to examine the influence of NLRP3 inflammasome on the efficacy of ICB, they used three groups of lymphoma-bearing mice: the first was treated with the MCC950 inhibitor, the second with the anti-PDL1 antibody, and the latter with combination therapy. This evidence concerns the gene NLRP3 and lymphoma.